Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Seccombe, D
Phase 1b (CT-388, 24 weeks): Phase 2 (CT-388 up to 24 mg, 48 weeks): GI AEs described as "mild-to-moderate" and "generally consistent with incretin class" Discontinuation due to AEs: 5.9% (vs 1.3% placebo) Weight loss: 22.5% placebo-adjusted at 48 weeks Key characteristics: Phase 1b showed very high absolute GI rates during titration, but these declined substantially during maintenance Phase 2 data showed a much more favorable tolerability profile with a low discontinuation rate of 5.9% The signal-biased design appears to provide sustained receptor activation without desensitization Despite high initial GI rates, very few patients discontinued, suggesting events were transient and manageable Phase 3 (ENITH program) planned for 2026 Bioglutide (NA-931)# Bioglutide is the first oral quadruple receptor agonist (GLP-1, GIP, glucagon, and IGF-1), developed by Biomed Industries
Avoid starting new patients on GLP-1 treatment until supply stabilizes
Effect of L-carnitine on dilated cardiomyopathy in 36 cases
The SURMOUNT trials showed tirzepatide at 15 mg weekly resulted in approximately 22% body weight reduction
US$ 24.15
US$ 26.59
US$ 21.44
US$ 23.58
US$ 26.00
